Treatments associated with a resistance (e.g. Erlotinib in EGFR T790M mutant NSCLC) or standard of care treatments with no evidence for a potential clinical benefit due to absence of an alteration in the patient (e.g. Pembrolizumab in MSS CRC or in PD-L1 negative NSCLC). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.